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Abstract
Kidney transplantation has become the primary method of treating severe chronic renal
failure. The first successful kidney transplant was performed in 1954 in Boston, the graft
was in function for 7 years, and patient died because of the heart disease. Cardiovascu-
lar disease is the leading cause of death in patients with a transplanted kidney. Despite
the fact that patients with a transplanted kidney are highly susceptible to infections and
have an increased tendency to develop malignant diseases, these patients die mainly of
cardiovascular disease. Patients with a transplanted kidney are exposed to atherogenic
risk which is associated with previous dialysis treatment and the use of immunosup-
pressive drugs. An excessive risk of developing cardiovascular disease in patients with
a transplanted kidney is due to the high frequency and accumulation of atherogenic risk
factors before and after transplantation. Pre-transplant cardiovascular disease is a major
risk factor for the development of post-transplant cardiovascular disease. Risk factors
for the development of cardiovascular diseases in patients with a transplanted kidney
are divided into traditional and nontraditional. Traditional risk factors such as immuta-
ble (age, gender, and inheritance) and variable (smoking, hyperlipidemia, hypertension,
obesity, diabetes mellitus, physical activity, stress). Nontraditional risk factors such as
risk factors related to the status of transplantation and its treatment and risk factors
associated with chronic regression in allograft function. The most common cardiovas-
cular diseases in patients after kidney transplantation are as follows: ischemic heart
disease, congestive heart failure and left ventricular hypertrophy. Of all cardiovascular
complications, ischemic heart disease is by far the most common cause of mortality
(more than 50%) in patients with a transplanted kidney. Frequency of left ventricular
hypertrophy ranges from 50 to 70% in patients with a transplanted kidney. Early detec-
tion of high-risk patients for the development of cardiovascular diseases allows timely
application of an appropriate therapeutic strategy that ensures high survival rates for
patients with a transplanted kidney.
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1. Introduction
1.1. History of transplantation
Organ transplantation is one of the greatest achievements in history of medicine in the twen-
tieth century. Kidney transplantation has become the primary method of treating severe
chronic renal failure. The first successful kidney transplant was performed in 1954 in Boston,
the graft was in function for 7 years, and patient died because of the heart disease. Over the
past decades, organ transplantation has achieved incredible proportions through the develop-
ment of surgical techniques, organ preservation methods, new diagnostic procedures, but, in
particular, through discovery of powerful immunosuppressants.
1.2. Kidney transplant recipients
1.2.1. Becoming a kidney recipient
Kidney transplantation has become the primary method of treating severe chronic renal
failure. After kidney transplantation, life is better, more quality and longer than during dialy-
sis. It is recommended that all patients in end-stage kidney disease should be considered as
potential kidney transplant recipients no matter of absolute contraindications. Because of the
lack of available organs for transplant and all possible risks of immunosupresive drugs, careful
consideration and adequate preparation of patients are indispensable. All studies related to the
preparation of the transplant patient are covered by a protocol that includes detailed medical
history, physical examination, system review including an examination by a psychologist. To
be considered as transplant recipient, patient should be put on the transplant program’s
waiting list. To select recipients from a deceased donor in our country, we use the prescribed
criteria. Among these criteria, an important place includes a blood type, match between the
recipient and the donor, tissue typing, length of time on the dialysis and sensibility of the
recipient [1].
1.2.2. Contraindications for kidney transplantation in the recipient
Contraindications for kidney transplantation in the recipient may be absolute, relative and
temporary. Absolute contraindications: contraindications for general anesthesia or surgery,
metastatic malignancy, refractory cardial decompensation, chronic respiratory insufficiency,
advanced coronary or cerebrovascular disease, coagulopathy, chronic infection, mental retar-
dation, psychosis, alcoholism, drug addiction. Relative contraindications: frequent respiratory
infections, heart failure with frequent exacerbations, frequent digestive bleeding, previous
malignancy, primary renal disease with a high degree of postoperative recurrence.
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Temporary contraindications: tuberculosis and other chronic infections, bleeding, unexplained
focal infection, unresolved bladder anomalies, arterial hypertension with complications, pro-
nounced secondary hyperparathyroidism.
1.3. Kidney transplant donors
The kidney can be transplanted from deceased-donor (cadaveric transplantation) or from
living-donors: genetically related (living-related) or nonrelated (living-unrelated) transplants,
depending on whether a biological relationship exists between the donor and recipient. The
basic prerequisite is for the donor to be mentally and physically healthy and willing to give the
kidney. Numerous studies have shown that there are no proteinuria, hypertension or renal
insufficiency in the carefully selected donors at 10 and 20 years after the kidneys in relation to
the healthy population.
1.4. Pre-emptive kidney transplant
A pre-emptive kidney transplant (before kidney function deteriorates to the point of needing
dialysis) should be offered to all candidates for transplantation who have a potential live
donor. Earlier kidney transplants from a cadaveric donor can be offered to all potential
recipients, but of particular importance are for children and patients with diabetes mellitus.
To do the preemptive kidney transplantation, two conditions must be fulfilled: the patient
must have irreversible and progressive renal impairment and the creatinine clearance must be
less than 15 ml/min. Numerous studies have shown that survival of patients and calves after
pre-emptive kidney transplantation was the same or even better than the transplantation done
after the dialysis began [2].
1.5. Surgical procedures in kidney transplantation
Transplantation of the kidneys is a surgical procedure where the donor’s kidney is placed in
the lower part of the abdominal cavity of the recipient. The renal artery and veins connect to
the large pelvic artery and vein of the recipient. The urinary tract of the transplanted kidney is
attached to the recipient’s bladder.
1.6. Immunosuppressive therapy
Renal transplantation is an important form of treatment for patients with terminal renal
insufficiency. However, an obstacle to the success of the greatest number of transplants repre-
sents the immune response of a recipient directed against the transplanted kidney.
Due to the constant immunological response to renal allograft, permanent immunosuppres-
sive therapy is carried out to prevent graft rejection. Theoretically, it should not be used only
on identical twins. The basis of immunosuppression is a calcineurin inhibitor that is combined
with corticosteroids and mycophenolate mofetil (Cellcept). Immunosuppressive drugs have
enabled the success of organ transplantation, but they do not only act to prevent rejection of
the transplanted organism but also they have numerous side effects on the body. Important
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side effects of immunosuppressants are the increased risk of infection and the atherogenic
effect of immunosuppressive therapy.
1.7. Transplantation complications
The early period after kidney transplantation relates to the first 2 months after the surgery [3].
Acute surgical complications (bleeding, thrombosis of the transplanted kidney) are common in
first few days after surgery, other clinical and immunological complications occur later.
Reactions of graft rejections are classified into four types based on the clinical picture, but
differ in pathogenesis, histomorphological picture, and reactions own flow [4]. Those are
hyperactivity, acceleration, acute and chronic rejection. Hyperacute rejection occurs in the first
minutes or hours after kidney transplantation. Accelerating rejection begins 5–7 days after
kidney transplantation and is demonstrated by rapid deterioration of the graft function. Acute
rejection usually occurs from the fifth day to the end of the third month after kidney trans-
plantation, but it can occur later on. Chronic graft rejection signifies the process in which
transplanted kidney progressively deteriorates for several months and years, although the
transplantation was successful in the first place. Other complications after kidney transplant
are: urological complications, cardiovascular diseases, infections, gastrointestinal tract and
liver diseases, malignant tumors, skin, bone and muscle diseases [4].
2. Risk factors for cardiovascular disease after kidney transplantation
Risk factors for the development cardiovascular diseases in patients with a transplanted
kidney are more common than the risk factors in the general population.
They include traditional risk factors, such as arterial hypertension, diabetes mellitus, hyperlip-
idemia, and nontraditional risk factors associated with reduced glomerular filtration, such as
anemia, hyperhomocysteinemia, or factors typical for transplantation, including direct effects
of immunosuppression or rejection [5].
Patients with a transplanted kidney are exposed to atherogenic risk which is associated with
previous dialysis treatment and the use of immunosuppressive drugs. An excessive risk of
developing cardiovascular disease in patients with a transplanted kidney is due to the high
frequency and accumulation of atherogenic risk factors before and after transplantation. Pre-
transplant cardiovascular disease is a major risk factor for the development of post-transplant
cardiovascular disease [6].
Cardiovascular diseases represent the most frequent cause of morbidity and mortality in
patients at the end stage of renal diseases. Left ventricle hypertrophy occurs in 75% of patients
treated by chronic dialysis. The prevalence of coronary heart disease in patients who are
treated by chronic hemodialysis is 40%. The frequency of congestive heart failure in patients
undergoing hemodialysis is 46%. Cardiac diseases represent the leading cause of death of
dialyzed patients of which sudden cardiac death is the most frequent that is responsible for
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around 25% of all deadly outcomes. The rate of cardiovascular mortality in patients undergo-
ing chronic dialysis is nearly 9% per annum. In patients treated by chronic dialysis, the risk of
development of CVD is 10–20 times higher than in general population. Uremic milieu contrib-
utes to occurrence of atherosclerosis and atherosclerotic cardiovascular complications and
often the development of accelerated, galloping atherosclerosis is present. The patients under-
going chronic dialysis are exposed to traditional and nontraditional risk factors for the devel-
opment of cardiovascular complications. Nontraditional risk factors are the consequences of
the uremic milieu and are related with the dialysis technique itself, and they are divided into
hemodynamic and metabolic risk factors. Hemodynamic risk factors are anemia, retention of
sodium and water, arteriovenous (AV) fistula, while the metabolic risk factors are hyperhomo-
cysteinemia, hypoalbuminemia, oxidative stress, microinflammation and secondary hyper-
parathyroidism.
Risk factors for cardiovascular diseases in patients with a transplanted kidney are divided into
traditional and nontraditional [5]: traditional risk factors are: immutable (age, gender, and
inheritance), variable (smoking, hyperlipidemia, hypertension, obesity, diabetes mellitus, physi-
cal activity, and stress); and nontraditional risk factors are: risk factors related to the status of
transplantation and its treatment (immunosuppressive agents, graft rejection, and viral infection
—cytomegalovirus) and risk factors associated with chronic regression in allograft function
(anemia, volume load, hyperhomocysteinemia, oxidative stress, secondary hyperparathyroid-
ism, and microinflammation).
2.1. Traditional risk factors
Smoking is not only a risk factor for the development of cardiovascular diseases, but is also
associated with the risk of developing chronic kidney disease defined as a reduction in glo-
merular filtration to <45 ml/min/1.73 m2. Long-term smoking of more than 20 cigarettes per
day is associated with 1.52 times higher relative risk of chronic kidney disease [7]. For com-
parison, smoking and obesity are associated with a 1.77 times higher relative risk of chronic
kidney disease. These risks are more conspicuous in men than in women. Smoking begins and
improves the process of atherosclerosis in the blood vessels. In various studies, it has been
shown that smoking leads to cardiovascular complications, reduces survival of the patient and
graft, and its effect on patient survival is similar to the same one on patients with diabetes
mellitus [8]. Smoking cigarette is an independent risk factor for the development of cardiovas-
cular events in patients with a transplanted kidney. In the population of patients with
transplanted kidney, the prevalence of smoking is 25%, and the smoking cessation includes
pharmacological therapy—NRT (nicotine replacement therapy).
Risks of cardiovascular diseases increase with increasing body weight because it increases the
blood pressure, serum lipids, and glucose intolerance. A particularly harmful factor is the
central obesity characterized by an increase in intra-abdominal fat tissue. Central obesity
(waistline >88 cm for women and >102 cm for men) is a risk factor for declining allograft
function in patients with a transplanted kidney. Obesity fosters the development of the insulin
resistance, diabetes mellitus, ischemic heart disease, and reduces survival of allograft [9].
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A cohort study by Adabag of 14,941 men and women, aged 45–64 years, showed that obesity
was associated with an increased risk of sudden cardiac death [10]. According to research by
Chan, obesity is a risk factor for the development of cardiovascular disease following kidney
transplantation [11]. Although the role of obesity in the pre-transplant period is uncertain,
after kidney transplantation, obesity increases the risk of graft failure and mortality.
Weight loss reduces and changes other risk factors for the development of cardiovascular
disease [12]. Metabolic syndrome is a risk factor for the development of cardiovascular disease
in patients with a transplanted kidney. It is characterized by obesity (central type of obesity),
physical inactivity, hypertension (arterial blood pressure greater than 130/80 mmHg), hyper-
lipidaemia (triglycerides greater than 1.7 mmol/l, HDL cholesterol less than 1.0 mmol/l in men
and less than 1.3 mmol/l in women) and systemic insulin resistance (fasting blood sugar greater
than 6.5 mmol/l). Six years after kidney transplantation, 63% of patients have criteria for
metabolic syndrome, reduced survival of allograft and an increased number of cardiovascular
incidents [9].
Diabetes mellitus is one of the most common causes of renal disease, this disease independent
and in itself increases the risk of cardiovascular disease. The results of two large clinical studies,
Framingham Study and Multiple Risk Factor Intervention Trial (MRFIT) show that diabetes
mellitus doubles the possibility of coronary artery disease in men and triples the risk of
coronary artery disease in women [13]. Diabetes mellitus is a relatively common complication
after kidney transplantation and is defined as a fasting glucose greater than 7 mmol/l. The
incidence of diabetes mellitus is between 3.6 and 18% and depends mainly on immunosuppres-
sive therapy. Kidney transplantation can lead to the deterioration of existing diabetes mellitus
or to the development of “de novo” diabetes mellitus. The most common cause of post-
transplantation diabetes mellitus is corticosteroid therapy, and it depends on immunosuppres-
sive therapy. The two main mechanisms by which corticosteroids cause diabetes mellitus are
inducing insulin resistance and increasing body weight [14]. Immunosuppressive drugs can
lead to the development of diabetes. The prevalence of post-transplant diabetes in patients
treated with cyclosporin ranges from 2.5 to 20%. The treatment of diabetes in hospitalized
transplant recipients requires attention to a multitude of factors that can impact glycemic
control and influence the risk for adverse effects. Methods to manage hyperglycemia vary
among transplant centers and also vary according to whether the patient is immediately post-
transplant or is being admitted in the post-transplant setting for another issue. Immediately
after transplantation in post-transplant we use frequently require IV insulin infusion protocol.
Once iv requirements are established and stable, switch to insulin every 8 h plus fast-acting
correction insulin every 4–6 h.
The prevalence of post-transplant hypertension is between 60 and 85%. Causes of hyperten-
sion in patients with a transplanted kidney are as follows: stenosis of graft renal artery,
presence of native kidneys, immunosuppressive therapy, graft dysfunction, genetic predispo-
sition of donors and recipients. Native kidneys and pre-transplant hypertension have been
described as independent factors associated with post-transplant hypertension. Native kidney
of recipient can cause systemic hypertension through the renin-angiotensin system. Immuno
suppressive drugs are also responsible for the appearance of hypertension in patients with a
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transplanted kidney. It is believed that corticosteroids aggravate hypertension through hemo-
dynamic and hormonal disorders as well as retention of salt and water. The role of cyclosporin
in the development of hypertension in the transplantation of the heart, liver and bone marrow,
as well as in patients with uveitis and diabetes mellitus, has been demonstrated, while its role
in kidney transplantation is controversial. On the one hand, cyclosporin can cause hyperten-
sion with its nephrotoxic effect, and on the other hand, if cyclosporin prevents chronic rejec-
tion, it may delay the occurrence of hypertension. In two large retrospective studies with a
follow-up period of 2 and 3 years, the prevalence of hypertension remained stable over time,
but in the group of patients treated with ciclosporin, the prevalence of hypertension increased
by 25% compared to patients treated with azathioprine [15]. Tacrolimus therapy causes hyper-
tension, whose mechanism is probably similar to cyclosporin-induced hypertension. It is
a general opinion that the main cause of hypertension after renal transplantation is chronic
graft dysfunction or chronic graft nephropathy. Hypertension is often the first clinical sign of
chronic rejection. It is known that arterial hypertension is a risk factor for cardiovascular
disease in the general population. In a retrospective analysis, Ponticelli and associates have
found a higher number of cardiac infarcts after kidney transplantation in patients with hyper-
tension than in normotensive patients [16]. Arterial hypertension correlates with cardiovascu-
lar disease after transplantation [17]. In most cases for treatment post-transplant hypertension,
routine antihypertensive treatment is effective. We can use ACE inhibitors, beta blockers and
calcium channel blockers.
Hyperlipidemia is known as the traditional risk factor for the development of cardiovascular
diseases, both in the general population and in the population of patients with terminal stage of
renal failure. Several observational studies have shown that total cholesterol and low-density
lipoproteins (LDL) are one of the most important independent factors of cardiovascular mor-
bidity and mortality [18]. Patients with renal function impairment have significant changes in
the metabolism of lipoproteins, whose exact role in the pathogenesis of atherosclerosis in these
patients is still controversial [19]. Hyperlipidemia can occur already after 3 months of trans-
plantation and does not resolve spontaneously, and in most patients, it can persist for a very
long, even 10 or more years after kidney transplantation [20]. Patients with a transplanted
kidney usually have an increased total cholesterol, LDL cholesterol and triglycerides, while
HDL cholesterol is usually normal or even high, although its composition may be pathological
[21]. Immunosuppressive drugs such as corticosteroids, cyclosporin, tacrolimus and, in partic-
ular, sirolimus contribute to the development of post-transplant hyperlipidemia, usually
depending on the dose of medicine [22]. Many epidemiological studies of patients with a
transplanted kidney showed a correlation between elevated total cholesterol, triglyceride, LDL
and incidence of cardiovascular diseases, the same as a low level of HDL is associated with an
increase in cardiovascular risk [23]. Hyperlipidemia in patients with a transplanted kidneymay
affect the progression of chronic graft nephropathy. Based on data about the prevention of
cardiovascular disease, it is known that the reduction of LDL-cholesterol by 1 mmol/l over
4–5 years reduces the risk of coronary and cerebrovascular incidents by 25%. Extrapolation
from general population studies and some data in kidney transplant patients support the view
that the assessment and treatment of dyslipidemias should be part of routine post-renal trans-
plant care. For treating hyperlipidemia in kidney transplant patient, we use statins.
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2.2. Risk factors related to the status of transplantation and its treatment
In patients who at the moment of transplantation have no signs of atherosclerosis, reduced
graft function and immunosuppressive therapy may cause hypertension, dyslipidemia, diabe-
tes mellitus, and proteinuria, which can lead to myocardial infarction, stroke, or peripheral
vascular disease.
Allograft function disorder is a risk factor for the development of cardiovascular disease [24].
A year after renal transplantation, chronic allograft disease at stage 3 (glomerular filtration
<60 ml/min/1.73 m2) has 60%, and in stage 4 (glomerular filtration value <30 ml/min/1.73 m2)
has 15% of patients [25]. With the decline in the allograft function, nontraditional risk factors
appear. They occur when the glomerular filtration value falls below 60 ml/min/1.73 m2, and
especially when it is below 45 ml/min/1.73 m2.
Reduced function of transplanted kidney in transplant recipient is an independent and impor-
tant risk factor for the development of cardiovascular diseases due to adverse effects on
hypertension, anemia, dyslipidemia, hyperhomocysteinemia [26]. The American National
Kidney Foundation (NKF) reported that the value of glomerular filtration (GFR) measured or
estimated is a better parameter of renal function than serum creatinine only [27]. The preva-
lence of left ventricular hypertension is inversely proportional to the level of glomerular
filtration. In one study, the frequency of left ventricular hypertension was 45, 31 and 27% in
patients with creatinine clearance <25, 25–50, and >50 ml/min [28].
2.3. Risk factors relating to chronic decline in graft function
With an increased risk of cardiovascular complications, homocysteine, infection, pathological
coagulation and fibrinolysis are associated.
Anemia is a risk factor for the development of cardiovascular disease in patients with a
transplanted kidney. The American Society of Transplantation (AST) defines anemia as a
hemoglobin concentration lower than 120 g/l in men and lower than 110 g/l in women [29].
Anemia occurs in 20–60% of patients with a transplanted kidney, and its prevalence is the
highest in the early post-transplant period (6–12 months after kidney transplantation). The
main causes of its development in the early post-transplant period are: blood loss due to
surgery, abrupt termination of erythropoietin administration, iron deficiency, bone marrow
suppression caused by induction therapy, increased erythropoietin resistance due to infection
(viral infection) and/or inflammatory status caused by systemic immune response on the
presence of alloantigens, the use of drugs (mycophenolate mofetil). Reduced production of
endogenous erythropoietin due to loss of allograft function, erythropoietin resistance due to
secondary hyperparathyroidism and chronic microinflammatory disease are the main causes
of anemia in late post-transplantation [30].
Post-transplantation anemia (a hemoglobin less than 110 g/l 3 months after renal transplanta-
tion) was associated with the development of congestive heart failure, a lower survival rate of
allograft and patient, and a higher rate of acute rejection [31]. The relative risk for the cardio-
vascular incident was 1.32 with a decrease in hemoglobin by 0.5 g/dl, which is just slightly less
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than the relative risk of 1.37 related to an increase in systolic pressure of 15 mmHg. Anemia
together with hypertension leads to left ventricular hypertrophy.
Treatment of patients with transplanted kidney and post-transplant anemia should be started
with erythropoietin, when the hemoglobin concentration is less than 110 g/l and the target
hemoglobin level should be 110–120 g/l.
Homocysteine concentration is an independent risk factor for cardiovascular disease after
kidney transplantation [32]. In patients with a transplanted kidney, the concentration of homo-
cysteine decreases compared to patients treated with dialysis but is higher than the concentra-
tion of homocysteine in healthy population, so hyperhomocysteinemia is common in patients
after kidney transplantation [33]. For the treatment of hyperchomocysteinemia, we use folate
and Vitamin B (12).
There is clear evidence that elevated levels of fibrinogen, factor VII, and von Willebrand factor
in the general population are associated with an increased risk of acute insult or coronary
disease [34]. These factors have also been elevated in patients following kidney transplanta-
tion, in more patients with cardiovascular disorders than in patients who do not have them.
Secondary hyperparathyroidism is a risk factor for the development of cardiovascular disease
in patients with a transplanted kidney [35]. After transplantation of the kidney, hyperparathy-
roidism is maintained in 50% of patients, characterized by hypercalcaemia, hyperphospha-
temia and increased parathormone concentration [36]. Secondary hyperparathyroidism in
post-transplantation may also occur new, as a consequence of the decline in the function of
the allograft and the lack of calcitriol. The disorder of metabolism of calcium and phosphate
results in calcification of peripheral arteries, including coronary artery calcification. Cinacalcet
may be useful in the treatment of persistent hyperparathyroidism after kidney transplant.
The effect of local inflammatory stimulus such as products of the oxidation process, the end
products of glycosylation and chronic infectious processes alter the blood vessel in terms of the
development of atherosclerosis. Microinflammation is a risk factor for the development of
atherosclerotic cardiovascular diseases in patients with a transplanted kidney [24]. These
patients have a low level of microinflammation as a consequence of a systemic immune
response to the presence of all antigens but also because of chronic infections [25]. C-reactive
protein (>5 mg/l > 0.5 mg/dl) is associated with an increased risk of developing cardiovascular
events in the population of patients with a transplanted kidney.
Proteinuria occurs in one-third of post-transplant patients and is a risk factor for the develop-
ment of cardiovascular disease in patients with a transplanted kidney [37].
3. Cardiovascular disease in patients with transplanted kidney
Thanks to the progress in histocompatibility testing and better immunosuppressive therapy,
graft survival has increased, so that the leading cause of graft loss after transplantation has
been the death of a patient with functional graft. Cardiovascular disease is the leading cause of
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death in patients with a transplanted kidney [38]. Despite the fact that patients with a
transplanted kidney are highly susceptible to infections and have an increased tendency to
develop malignant diseases, these patients die mainly of cardiovascular disease. Although
kidney transplantation, in contrast to dialysis, reduces the risk of cardiovascular disease by
restoring kidney function, it also brings new risk factors related to the status of transplantation
and its treatment and risk factors related to the chronic decline in the function of the allograft.
The increased incidence of cardiovascular diseases in patients with transplanted kidney is a
consequence of the high prevalence of risk factors for the development of cardiovascular
diseases in these patients. The incidence of cardiovascular disease in patients with a
transplanted kidney is three to five times higher than in the general population [39]. A
cardiovascular event with congestive heart failure or coronary heart disease was manifested
in almost 40% of patients 36 months after kidney transplantation [9]. Cardiovascular disease is
the most common cause of death in transplanted patients, accounting for 35–50% of all causes
of death, and occurs at least two times more often than in the general population [40]. Most
kidney recipients die with functional graft and half of these patients die due to ischemic heart
disease or other vascular diseases [41].
The most common cardiovascular diseases in patients after kidney transplantation are as
follows: ischemic heart disease, congestive heart failure and left ventricular hypertrophy [6].
Of all cardiovascular complications, ischemic heart disease is by far the most common cause of
mortality (more than 50%) in patients with a transplanted kidney [41]. Frequency of left
ventricular hypertrophy ranges from 50 to 70% in patients with a transplanted kidney [42].
Left ventricular hypertrophy is associated with an increased degree of ventricular arrhythmias.
In Europe, cardiovascular disease account for 36% of the total mortality of patients with a
transplanted kidney [43]. In the United States, the annual mortality rate of cardiovascular
diseases in these patients is 0.54% and is approximately twice as high (0.28%) than in the
general population [39].
Ischemic heart disease causes 53% of deaths in patients with transplanted kidney and pre-
served graft function. The risk of mortality from ischemic heart disease is 6.4 times higher in
nondiabetic transplanted renal patients, 8.6 times higher in dialysis patients and 20.8 times
higher in transplanted renal patients with diabetes than in the general population [41]. Diag-
nostic strategy for early detection of patients with an increased risk of developing asymptom-
atic disorders of the systolic and diastolic function of the left ventricle should include:
echocardiographic examination, tests for coronary artery disease and tests for the determina-
tion of myocardial function (BNP, Tt-pro BNP). In a study of Aakhus and associates on
cardiovascular diseases in patients with a transplanted kidney, involving 406 patients with a
transplanted kidney, the mean annual mortality was 4.4, and 74% of them were cardiovascular
causes of mortality [44].
3.1. Left ventricular hypertrophy
The most significant risk factors for the development of left ventricular hypertrophy are as
follows: hypertension, arteriosclerosis, secondary aortic stenosis and anemia.
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Left ventricular hypertrophy is a risk factor for the unfavorable outcome of patients with a
transplanted kidney. The selection of patients with an increased risk of left ventricular hyper-
trophy, the timely application of appropriate treatment, the achievement and maintenance of
the target values of risk factors, lead to decrease of the development and regression of existing
left ventricular hypertrophy, reduction in the rate of cardiovascular morbidity and mortality,
and improve the quality of life of patients with a transplanted kidney.
Left ventricular hypertrophy is present in most patients who begin treatment by replacing
renal function and are associated with poor outcome. Time spent on dialysis can also affect the
development of left ventricular hypertrophy. Transplantation of the kidneys leads to the
withdrawal of left ventricular hypertrophy together with the normalization of blood pressure.
The regression of left ventricular hypertrophy continues during the first 2 years after trans-
plantation. Older age and hypertension can slow down this process [45].
The presence of left ventricular hypertension as well as the weak systolic function of the left
ventricle before transplantation are related to an increased mortality after renal transplantation
during 7.5-year follow-up, while other traditional risk factors such as hypertension, hyperlip-
idemia and smoking did not show such a connection. On cardiography of the heart made
4 months after transplantation, only left ventricular hypertension had a strong association with
poor prognosis during monitoring [46].
3.2. Heart failure
Heart failure is a clinical syndrome characterized by reduced tolerance of physical activity and
overload volume. The incidence of congestive heart failure in patients with a transplanted
kidney is two to five times higher than the incidence in the general population [47]. The
incidence of congestive heart failure in patients with a transplanted kidney was 10.2%
12 months after transplantation and 18.3% 36 months after transplantation [48].
In a study of Higashi and associates, 11 out of 190 (5.8%) kidney recipients, with preserved left
ventricular systolic function and the presence of diastolic left ventricular dysfunction, devel-
oped a postoperative edema of the lungs [49].
Diastolic left ventricular dysfunction is present in 45% of patients with a transplanted kidney.
The clinical presentation is the same as in all other patients with cardiac insufficiency. The
following symptoms are reported: difficulty breathing, intolerance of physical activity, edema
of the lower extremities and stomach.
Treatment: the first measure is to reduce physical activity and reduce salt intake. If this is not
enough, medication therapy is started with a combination of diuretics, ACE inhibitors and
digitalis.
3.3. Ischemic heart disease
Ischemic heart disease (IHD) is the most common disease in the large group of all cardiovas-
cular diseases. The prevalence of ischemic heart disease in patients with a transplanted kidney
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is five times higher than in the general population. The main cause of ischemic heart disease is
atherosclerosis of the coronary arteries, and in patients with transplanted kidney there are
many risk factors that contribute to atherosclerosis: elevated arterial blood pressure, lipid
metabolism disorder, microinflammation, hyperhomocysteinemia, oxidative stress and sec-
ondary hyperparathyroidism.
In patients with a transplanted kidney, there is a high risk of sudden cardiac death. The main
causes are coronary arterial heart disease, left ventricular hypertrophy, and reduced coronary
perfusion. In patients with a transplanted kidney, the prevalence of coronary heart disease is
five times higher than the general population [6].
In all patients with ischemic heart disease, the following should be done: detailed anamnesis
and physical examination, ECG at rest, blood biochemical analysis (lipids, glucose, creatinine,
urea, hepatogram, complete blood count, uric acid, fibrinogen, hsCRP, etc.) echocardiographic
examination, ergometric testing. In patients with transplanted kidney, the risk factors for the
development of atherosclerosis should be controlled in the primary prevention and prevention
of coronary artery disease development. In clinical practice, patients with acute myocardial
infarction with elevation of ST connectors are using modern reperfusion therapy (thrombolysis
or percutaneous coronary intervention). Medical treatment implies the use of anti-aging ther-
apy, statins and beta blockers.
3.4. Valvular heart disease, heart rhythm disorders, and pericardial disease
Valvular heart disease is common in patients with chronic dialysis. Current knowledge of
heart valve disease (the evolution of pre-dialysis disease or the emergence of de novo diseases
of the heart valve) in patients following kidney transplantation is scarce. In the literature, there
are few data about heart rhythm disorders in patients with transplanted kidney. In a study by
Sever and associates on the frequency of pericarditis in patients following kidney transplanta-
tion, an incidence of 2.4% was observed [50].
The development of pericarditis in patients with a transplanted kidney may contribute to the
use of immunosuppressive therapy as it increases the risk of infection [51].
4. Assessment of the risk of cardiovascular disease in asymptomatic
patients with a transplanted kidney
Cardiovascular diseases are the main cause of morbidity and mortality in post-transplant
patients [52]. The risk assessment of cardiovascular disease in asymptomatic patients with a
transplanted kidney is of great practical importance because it allows the identification of
patients at high risk for cardiovascular events, which further allows timely intervention before
the disease develops. To assess the risk of cardiovascular disease in asymptomatic patients
with a transplanted kidney, we can apply the scores used for assessment of cardiovascular risk
in general population. The scores for the general population are the Systematic Coronary Risk
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Evaluation SCORE system, the Prospective Cardiovascular Munster PROAM score system,
and the National Cholesterol Education Program Adult Treatment Panel III NTEP ATP III [53].
The new risk assessment model is based on the Heart Score system (Systematic Coronary Risk
Evaluation). The Heart Score Risk Card has been developed on the basis of large prospective
studies in Europe and predicts the fatal outcomes of cardiovascular disease for 10 years. The
Table 1. Heart score high risk map.
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assessment is based on the following risk factors: age, sex, smoking, systolic blood pressure,
total cholesterol, or cholesterol/HDL ratio. A high risk threshold based on a fatal cardiovascu-
lar outcome is defined as more than or equal to 5%.
Early detection of high-risk patients for the development of cardiovascular diseases allows
timely application of an appropriate therapeutic strategy that ensures high survival rates for
patients with a transplanted kidney (Table 1).
Assessing the patient’s risk of developing cardiovascular disease enables the identification of
patients at high risk for the development of cardiovascular events, which allow the interven-
tion before the disease develops. In asymptomatic patients, cardiovascular risk assessment
should be carried out and preventive activates should be performed accordingly. Patients with
established multifactorial risk should be subjected to preventive activities, and, if necessary to
medication therapy.
Several studies have shown that the use of standard scores in the assessment of the degree of
risk of cardiovascular disease in patients with renal disease is insufficient [54]. In these scores,
we use the following data: age, gender, blood pressure, lipid level, without taking into account
nontraditional risk factors for occurrence of cardiovascular diseases.
Nontraditional risk factors that are not included in these scores can play an important role in
the insufficient assessment of the risk of cardiovascular disease in patients with a transplanted
kidney. All these point should be consider by creating a new risk score that would include both
traditional and nontraditional risk factors for cardiovascular disease. It is recommended that
standard risk factors be enhanced with additional risk factors (e.g., homocystein, C-reactive
protein). Additional risk factors are recommended for increasing the precision of risk assess-
ment.
5. Conclusion
Cardiovascular disease is the leading cause of death in patients with a transplanted kidney.
The incidence of cardiovascular disease in patients with a transplanted kidney is 3–5 times
higher than in the general population. Risk factors for the development of cardiovascular
diseases in patients with a transplanted kidney are divided into traditional and nontraditional.
Traditional risk factors: immutable (age, gender, inheritance), variable (smoking, hyperlipid-
emia, hypertension, obesity, diabetes mellitus, physical activity, stress). Nontraditional risk
factors: risk factors related to the status of transplantation and its treatment (immunosuppres-
sive agents, graft rejection, viral infection - cytomegalovirus) and risk factors associated with
chronic regression in allograft function (anemia, volume load, hyperhomocysteinemia, oxida-
tive stress, secondary hyperparathyroidism, microinflammation). The most common cardio-
vascular diseases in patients after kidney transplantation are as follows: ischemic heart disease,
congestive heart failure and left ventricular hypertrophy. Of all cardiovascular complications,
ischemic heart disease is by far the most common cause of mortality (more than 50%) in
patients with a transplanted kidney. Frequency of left ventricular hypertrophy ranges from 50
to 70% in patients with a transplanted kidney. The incidence of congestive heart failure in
patients with a transplanted kidney is 2–5 times higher than the incidence in the general
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population. The incidence of congestive heart failure in patients with a transplanted kidney
was 10.2% 12 months after transplantation and 18.3% 36 months after transplantation. The risk
assessment of cardiovascular disease in asymptomatic patients with a transplanted kidney is
of great practical importance because it allows the identification of patients at high risk for
cardiovascular events, which further allows timely intervention before the disease develops.
To assess the risk of cardiovascular disease in asymptomatic patients with a transplanted
kidney, we can apply the scores used for assessment of cardiovascular risk in general popula-
tion. Several studies have shown that the use of standard scores in the assessment of the degree
of risk of cardiovascular disease in patients with renal disease is insufficient. It is recomm-
ended that standard risk factors be enhanced with additional risk factors (e.g., homocystein, C-
reactive protein). Additional risk factors are recommended for increasing the precision of risk
assessment. Assessing the patient’s risk of developing cardiovascular disease enables the
identification of patients at high risk for the development of cardiovascular events, which
allow the intervention before the disease develops.
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